Avalo Therapeutics Stock Fundamentals
| AVTX Stock | USD 7.90 0.30 3.95% |
Avalo Therapeutics fundamentals help investors to digest information that contributes to Avalo Therapeutics' financial success or failures. It also enables traders to predict the movement of Avalo Stock. The fundamental analysis module provides a way to measure Avalo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avalo Therapeutics stock.
At this time, Avalo Therapeutics' Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 11.9 M in 2025, whereas Depreciation And Amortization is likely to drop slightly above 172.6 K in 2025. Avalo | Select Account or Indicator |
Avalo Therapeutics Company Shares Outstanding Analysis
Avalo Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Avalo Therapeutics Shares Outstanding | 10.5 M |
Most of Avalo Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avalo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Avalo Shares Outstanding Historical Pattern
Today, most investors in Avalo Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Avalo Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Avalo Therapeutics shares outstanding as a starting point in their analysis.
Avalo Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Avalo Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Avalo Therapeutics has 10.5 M of shares currently outstending. This is 94.18% lower than that of the Biotechnology sector and 90.17% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 98.16% higher than that of the company.
Avalo Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Avalo Therapeutics's current stock value. Our valuation model uses many indicators to compare Avalo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Avalo Therapeutics competition to find correlations between indicators driving Avalo Therapeutics's intrinsic value. More Info.Avalo Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Avalo Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Avalo Therapeutics' earnings, one of the primary drivers of an investment's value.Avalo Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avalo Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Avalo Therapeutics could also be used in its relative valuation, which is a method of valuing Avalo Therapeutics by comparing valuation metrics of similar companies.Avalo Therapeutics is currently under evaluation in shares outstanding category among its peers.
Avalo Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Avalo Therapeutics from analyzing Avalo Therapeutics' financial statements. These drivers represent accounts that assess Avalo Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Avalo Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 308.1M | 194.0M | 47.4M | 2.5M | 2.3M | 2.2M | |
| Enterprise Value | 305.8M | 175.5M | 53.7M | (4.4M) | (3.9M) | (3.7M) |
Avalo Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Avalo Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Avalo Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Avalo Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (51.65) % | ||||
| Current Valuation | 1.64 M | ||||
| Shares Outstanding | 10.5 M | ||||
| Shares Owned By Insiders | 5.86 % | ||||
| Shares Owned By Institutions | 69.85 % | ||||
| Number Of Shares Shorted | 55.83 K | ||||
| Price To Book | 3.94 X | ||||
| Price To Sales | 101.16 X | ||||
| Revenue | 1.92 M | ||||
| Gross Profit | (9.34 M) | ||||
| EBITDA | (27.95 M) | ||||
| Net Income | (31.54 M) | ||||
| Cash And Equivalents | 11.25 M | ||||
| Cash Per Share | 1.20 X | ||||
| Total Debt | 537 K | ||||
| Debt To Equity | 5.62 % | ||||
| Current Ratio | 0.98 X | ||||
| Book Value Per Share | 2.18 X | ||||
| Cash Flow From Operations | (30.68 M) | ||||
| Short Ratio | 0.41 X | ||||
| Earnings Per Share | 94.42 X | ||||
| Target Price | 37.5 | ||||
| Number Of Employees | 19 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 82.95 M | ||||
| Total Asset | 20.99 M | ||||
| Retained Earnings | (335.13 M) | ||||
| Working Capital | 3.78 M | ||||
| Net Asset | 20.99 M |
About Avalo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avalo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avalo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avalo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 101.2 K | 96.1 K | |
| Total Revenue | 1.7 M | 1.6 M | |
| Cost Of Revenue | 1.2 M | 1.1 M | |
| Stock Based Compensation To Revenue | 2.08 | 1.69 | |
| Sales General And Administrative To Revenue | 6.14 | 5.74 | |
| Research And Ddevelopement To Revenue | 8.24 | 7.83 | |
| Capex To Revenue | 0.09 | 0.10 | |
| Revenue Per Share | 7.97 | 7.57 | |
| Ebit Per Revenue | (10.97) | (11.51) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.